Trials / Unknown
UnknownNCT03291860
Antimullerian Hormone as an Indicator for Ovarian Response
Antimullerian Hormone as an Indicator fo Ovarian Response in Women Receiving Long GnRH Agonist Protocol in Intracytoplasmic Sperm Injection Cycles
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 66 (estimated)
- Sponsor
- Ain Shams Maternity Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance. Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Ovum retrievum | assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2018-09-10
- Completion
- 2018-10-10
- First posted
- 2017-09-25
- Last updated
- 2017-09-25
Source: ClinicalTrials.gov record NCT03291860. Inclusion in this directory is not an endorsement.